merged_ozempic-kidney-disease.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article doesn't mention any percentage of U.S. adults with chronic kidney disease caused by Type 1 diabetes benefiting from Ozempic. It only discusses Type 2 diabetes.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article mentions Dr. Melanie Hoenig as a nephrologist who prescribes Ozempic to some patients, but doesn't mention her leading any clinical trial with the specific 30% reduction figure.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article doesn't mention any specific blood pressure medication by name, nor does it discuss synergistic effects with Ozempic.</other>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article doesn't specify any minimum threshold of cardiovascular mortality reduction required for FDA approval.</other>

<question_number>5</question_number>
<answer>N/A</answer>
<other>While the article mentions that patients sometimes take medications to manage vitamin D levels, it doesn't state that Ozempic exacerbates any vitamin deficiency.</other>

<question_number>6</question_number>
<answer>N/A</answer>
<other>The article doesn't specify how many years of clinical trial data Novo Nordisk submitted to the FDA.</other>

<question_number>7</question_number>
<answer>N/A</answer>
<other>The article doesn't mention any specific genetic marker related to gastrointestinal side effects from Ozempic.</other>

<question_number>8</question_number>
<answer>N/A</answer>
<other>The article doesn't name any competing drug that failed Phase 3 trials due to liver toxicity.</other>

<question_number>9</question_number>
<answer>N/A</answer>
<other>The article mentions that the FDA lists semaglutide as being in shortage, but doesn't provide a specific number of adults prescribed Ozempic for off-label weight loss.</other>

<question_number>10</question_number>
<answer>Gough</answer>
<other>Dr. Stephen Gough is identified as the senior vice president of global medical affairs at Novo Nordisk who commented on the minimal progress in kidney research over the past 20 years.</other>

<question_number>11</question_number>
<answer>24 percent</answer>
<other>The article states: "people with Type 2 diabetes and chronic kidney disease who took the drug had a 24 percent lower likelihood of experiencing a complication, like requiring dialysis or a transplant, compared to people who took a placebo."</other>

<question_number>12</question_number>
<answer>reducing inflammation</answer>
<other>The article states: "Researchers have theorized that Ozempic reduces inflammation throughout the body, including the kidneys."</other>

<question_number>13</question_number>
<answer>semaglutide</answer>
<other>The article states: "The F.D.A. lists semaglutide, the compound in Ozempic and the weight loss drug Wegovy, as currently in shortage."</other>

<question_number>14</question_number>
<answer>diet and exercise modifications</answer>
<other>The article mentions: "Doctors also routinely encourage lifestyle changes, including diet and exercise modifications, in part because these can help manage Type 2 diabetes."</other>

<question_number>15</question_number>
<answer>40 percent</answer>
<other>The article states: "Roughly 40 percent of people with Type 2 diabetes will develop chronic kidney disease, Dr. Gough said."</other>

<question_number>16</question_number>
<answer>dialysis or a transplant</answer>
<other>The article mentions that people who took the drug had a lower likelihood of experiencing complications "like requiring dialysis or a transplant."</other>

<question_number>17</question_number>
<answer>diet and exercise modifications</answer>
<other>The article states: "Doctors also routinely encourage lifestyle changes, including diet and exercise modifications, in part because these can help manage Type 2 diabetes."</other>

<question_number>18</question_number>
<answer>cardiovascular problems</answer>
<other>The article states that patients who took the drug "were less likely to die from cardiovascular problems."</other>

<question_number>19</question_number>
<answer>Food and Drug Administration</answer>
<other>The article states: "The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease."</other>